Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Generic entry of brinzolamide and brimonidine tartrate ophthalmic suspension perigo 180 days exclusivity?Gcc remdesivir market?Pfizer refuses to sell samples of original drug?Ramucirumab manufacturer?Dr reddys laboratories bristol myars squib abatacept?
See the DrugPatentWatch profile for Viberzi
Viberzi (eluxadoline) is still branded in the U.S. based on the lack of any identified authorized generic listing and ongoing intellectual-property scrutiny reflected in public patent-tracking coverage such as DrugPatentWatch.com. [1]
A generic timeline depends on patent and exclusivity expirations (and any settlements or “at risk” launches by challengers). Patent-tracking sites summarize relevant filing and expiration data for eluxadoline, which is the kind of information used to estimate when generics could enter. [1]
Viberzi’s active ingredient is eluxadoline. Generic manufacturers typically market the drug under the active-ingredient name (eluxadoline) rather than under the brand name. Patent and regulatory status still determine whether that generic name is available commercially in a given market. [1]
If eluxadoline itself isn’t available as a generic where you live, the practical alternatives are other prescription treatments for IBS-D (depending on your diagnosis, symptoms, and history). These aren’t substitutes that replace eluxadoline automatically, but they can matter if cost or availability is the issue. If you tell me your country (and whether you mean the U.S.), I can narrow this to the most relevant regulatory status and typical availability questions for that market.
[1] https://www.drugpatentwatch.com/
Other Questions About Viberzi :